Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Select your origin of interest
Human BRAF Protein expressed in HEK-293 Cells - ABIN2715104
Arnoux, Fina, Lambert, Balandraud, Martin, Ouafik, Kanaan, Roudier, Auger: Newly Identified BRAF Mutation in Rheumatoid Arthritis. in Arthritis & rheumatology (Hoboken, N.J.) 2016
Authors tested the mutation-specific BRAF V600E monoclonal antibody (clone VE1) in formalin-fixed, paraffin-embedded LCH samples from 26 pediatric patients using allele-specific real-time polymerase chain reaction (PCR) with a limit of detection of 0.5% as the comparative gold standard.
KRAS mutations were rarely found together and those in codons 12 and 13 conferred poor prognosis. For BRAF, more c.1781A>G (p.D594G) colorectal cancers (CRC)carried RAS mutations [14% (3/21)] compared with c.1799T>A (p.V600E) CRCs.For NRAS, 5% (3/60) of codon 61 mutant colorectal cancers had KRAS mutations compared with 44% (10/23) of codons 12 and 13 mutant colorectal cancers
Results indicate that in addition to being present in established BRAF-associated gliomas, BRAF mutations might be associated with epithelial features in high-grade gliomas, including sheet-like arrangement of polygonal tumor cells with a plump cytoplasm and astroblastic rosettes, and thus could potentially serve as a genetic marker for these features.
the present study identifies the WIPF1 (show WIPF1 Proteins) gene as having novel oncogenic functions and playing an important role in the invasiveness and aggressiveness of thyroid cancer when aberrantly up-regulated by the BRAF V600E/MAPK (show MAPK1 Proteins) pathway through its promoter demethylation.
BRAF mutation is associated with colonic neuroendocrine carcinoma.
c-Myc (show MYC Proteins), a downstream key effector of BRAF(V600E) signaling, was required for BRAF(V600E)-induced changes in lysine27-trimethylated histone H3 (show HIST3H3 Proteins) through regulating the components of the polycomb (show CBX2 Proteins) repressive complex 2 (PRC2) genes Ezh2 (show EZH2 Proteins), Suz12 and Jarid2 (show JARID2 Proteins) at both transcriptional levels via direct binding to their regulatory elements and post-transcriptional levels via repressing the miR (show MLXIP Proteins)-26a, miR (show MLXIP Proteins)-200b and miR (show MLXIP Proteins)-155.
Data show that depletion of SRY (sex determining region Y)-box 10 (show SOX10 Proteins) protein (SOX10 (show SOX10 Proteins)) sensitizes mutant proto-oncogene (show RAB1A Proteins) proteins B-raf (BRAF) melanoma cells to RAF (show RAF1 Proteins) inhibitors in vitro and in vivo.
A panRAF inhibitor, LY3009120, potently inhibited proliferation and tumor growth in BRAF/KRAS mutated colorectal tumors.
In the coBRIM phase III trial, the addition of cobimetinib, an MEK (show MAP2K1 Proteins) inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs (show AES Proteins)) in the coBRIM study
Report heterogeneity and frequency of BRAF mutations in primary melanoma samples.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.
Gene expression studies nominated TWIST2 (show TWIST2 Proteins) as a key effector downstream of BRAF.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.
BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.
BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.
mosaic expression of BRAF(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (show CDX2 Proteins)(Null)/BRAF(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF(V600E) potently interacted with CDX2 (show CDX2 Proteins) silencing to alter gene expression. Like human serrated lesions, CDX2 (show CDX2 Proteins)(Null)/BRAF(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis
TTM (show SLITRK1 Proteins) reduces copper levels and MAPK (show MAPK1 Proteins) signaling, thereby inhibiting BRAF(V600E)-driven melanoma tumor growth.
BRAF and ROKalpha (show ROCK2 Proteins) form independent RAF1 (show RAF1 Proteins) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (show EGF Proteins)).
Braf(V600E) expression, coupled with simultaneous p53 (show TP53 Proteins) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF(V600E) in metastasis.
Mechanistically, BRAF and RAF1 (show RAF1 Proteins) operate independently to balance MAPK (show MAPK1 Proteins) signaling: BRAF promotes ERK (show EPHB2 Proteins) activation, while RAF1 (show RAF1 Proteins) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3 (show PAX3 Proteins).
Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, B-Raf proto-oncogene serine/threonine-protein kinase
, proto-oncogene c-Rmil
, rmil serine/threonine-protein kinase
, serine/threonine kinase
, serine/threonine-protein kinase Rmil
, serine/threonine protein kinase BRAF
, serine/threonine-protein kinase B-raf-like
, B-raf protein